Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments

Volume: Volume 9, Pages: 19 - 27
Published: Feb 1, 2017
Abstract
Hepatocellular cancer (HCC) is a very fatal disease due to limited therapeutic options as well as due to its association with underlying chronic liver disease in the majority of cases. The immune evasion in HCC signifies a major barrier to the delivery of effective immunotherapy. Sorafenib is the only Food and Drug Administration-approved drug available with an overall response rate of 2%-3% and overall survival of 2.8 months. Chemotherapy has...
Paper Details
Title
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
Published Date
Feb 1, 2017
Volume
Volume 9
Pages
19 - 27
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.